指南与共识腹部技术与安全CTMR

通过比较临床指南推荐意见揭示直肠癌管理中的灰色区域与证据空白

Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines.
指南 / 共识 · Cancer Treat Rev · 2019-11-11

该研究选取26个反映非转移性和寡转移性直肠癌日常管理难题的临床问题,系统比较ESMO、NCCN、JSCCR、澳大利亚和安大略指南的推荐意见,采用4级分类系统评估一致性。结果显示指南在8个(30.8%)问题上基本/完全一致,9个(34.6%)问题上基本/完全不一致;诊断、分期和放射/病理报告模板相关问题常达成一致,而治疗相关主题多存在分歧。

要点

  • 指南在诊断、分期及放射/病理结构化报告问题上常达成一致,阅片报告可参照共识推荐。
  • 治疗相关主题(如非转移性和寡转移性直肠癌的治疗决策)是指南分歧的主要领域。
  • 指南一致与不一致的问题中,高级别证据支持比例分别为30%(3/10)和62.5%(10/16),差异未达统计学显著(χ2=2.6,p=0.106)。

核心结论

  • 非转移性和寡转移性直肠癌管理推荐意见在临床指南间存在显著差异,这种差异仅部分由缺乏高级别支持证据解释。

研究设计与样本

  • 研究选取26个反映非转移性和寡转移性直肠癌日常管理实际挑战的临床问题,提取ESMO、NCCN、JSCCR、澳大利亚和安大略指南的推荐意见,采用4级分类系统(相同/非常相似、相似、略有不同、不同)进行比较,并用χ2检验评估指南一致性与最高可用证据级别的关系。

诊断标准与关键数值

  • 指南间总体一致性评估为:基本/完全一致8个问题(30.8%),部分一致2个(7.7%),部分不一致7个(26.9%),基本/完全不一致9个(34.6%);指南一致的问题中高级别证据支持3/10(30%),指南不一致的问题中高级别证据支持10/16(62.5%)(χ2=2.6,p=0.106)。

临床应用与阅片要点

  • 阅片和报告时可参考指南在诊断、分期及放射/病理结构化报告方面常达成一致的推荐;治疗相关主题因指南分歧较大,需结合具体指南和证据级别审慎解读。

局限性

  • 指南间推荐意见差异仅部分由缺乏高级别支持证据解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: While the management of nonmetastatic and oligometastatic rectal cancer has rapidly evolved over the last few decades, many grey areas and highly debated topics remain that foster significant variation in clinical practice. We aimed to identify controversial points and evidence gaps in this disease setting by systematically comparing recommendations from national and international clinical guidelines.

METHODS: Twenty-six clinical questions reflecting practical challenges in the routine management of nonmetastatic and oligometastatic rectal cancer patients were selected. Recommendations from the ESMO, NCCN, JSCCR, Australian and Ontario guidelines were extrapolated and compared using a 4-tier classification system (i.e., identical/very similar, similar, slightly different, different). Overall agreement between guidelines (i.e., substantial/complete disagreement, partial disagreement, partial agreement, substantial/complete agreement) was assessed for each clinical question and compared against the highest level of available evidence by using the χ2 statistic test.

RESULTS: Guidelines were in substantial/complete agreement, partial agreement, partial disagreement, and substantial/complete disagreement for 8 (30.8%), 2 (7.7%), 7 (26.9%), and 9 (34.6%) clinical questions, respectively. High level of evidence supported clinical recommendations in 3/10 cases (30%) where guidelines were in agreement and in 10/16 cases (62.5%) where guidelines were in disagreement (χ2 = 2.6, p = 0.106). Agreement was frequently reached for questions regarding diagnosis, staging, and radiology/pathology pro-forma reporting, while disagreement characterised most of the treatment-related topics.

CONCLUSIONS: Substantial variation exists across clinical guidelines in the recommendations for the management of nonmetastatic and oligometastatic rectal cancer. This variation is only partly explained by the lack of supporting, high-level evidence.

来源:Cancer Treat Rev,查看原文。版权归原作者所有。

引用

  1. Bregni G, Akin Telli T, Camera S, et al. Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines. Cancer Treat Rev. 2019. PMID: 31756591. doi:10.1016/j.ctrv.2019.101930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。